The hormone estrogen regulates binge drinking in females, causing them to “pregame” – consume large quantities of alcohol in the first 30 minutes after it’s offered, according to a preclinical study led by scientists at Weill Cornell Medicine.
A Cornell Tech-led research group is in the early stages of developing a portable, inexpensive device that uses radio frequency signals and machine learning to measure lead contamination levels in soil.
Immune cells in the brain can partially break down large amyloid plaques characteristic of Alzheimer’s disease by latching on to them, forming a sort of external stomach and releasing digestive enzymes into the space, according to a preclinical study by Weill Cornell Medicine investigators.
Neuroscientist Gary Gibson, Ph.D. ’73, keeps a framed picture of a cell derived from the skin cells of a person with Alzheimer’s disease on his office wall.
The image is a memento of Gibson’s breakthrough…
A multicenter randomized, controlled clinical trial aims to test whether a minimally invasive treatment can relieve chronic pelvic pain and improve the quality of life for women with pelvic venous disease.
Reinforcement Learning, an artificial intelligence approach, has the potential to guide physicians in designing sequential treatment strategies for better patient outcomes but requires significant improvements before it can be applied in clinical settings.
Prostate cancer hijacks the normal prostate’s growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.
A newer hepatitis B vaccine was superior to an older type in inducing a protective antibody response among people living with HIV who didn’t respond to prior vaccination, according to a study led by a Weill Cornell Medicine investigator.
Weill Cornell Medicine has received a four-year, $1.4 million grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.
